<DOC>
	<DOCNO>NCT01149681</DOCNO>
	<brief_summary>This open-label , Phase II Clinical Trial Aplidin® ( plitidepsin ) Patients Primary Myelofibrosis post polycythemia vera/essential thrombocythemia ( Post-PV/ET ) Myelofibrosis .</brief_summary>
	<brief_title>Clinical Trial Aplidin® Patients With Primary Myelofibrosis</brief_title>
	<detailed_description>This trial try assess response rate ( ORR ) plitidepsin patient : primary myelofibrosis ( PMF ) , post-polycythemia vera myelofibrosis ( post-PV MF ) , post-essential thrombocythemia myelofibrosis ( post-ET MF ) . Besides , study result allow evaluate effect plitidepsin bone marrow ( BM ) peripheral blood histology determine quality life ( QoL ) symptom participant patient .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>1 . Diagnosis Primary Myelofibrosis ( PMF ) Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis ( postET/PV MF ) per revise World Health Organization ( WHO ) criterion . 2 . Highrisk intermediate2 risk Myelofibrosis ( MF ) define International Prognostic Scoring System ( IPSS ) ; intermediateI risk MF associate symptomatic splenomegaly/hepatomegaly and/or unresponsive available therapy . 3 . At least 18 year age , life expectancy ≥12 week . 4 . Able provide inform consent willing sign inform consent form ( ICF ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . 6 . Evidence acceptable organ function within seven day initiate study drug 1 . Previous treatment plitidepsin . 2 . Any following therapy within two week prior initiation study drug : chemotherapy ( e.g. , hydroxyurea ) , immunomodulatory drug therapy ( e.g. , thalidomide ) , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , erythropoietin . 3 . Incomplete recovery major surgery within four week study entry . 4 . Radiation therapy within four week study entry . 5 . Women childbearing potential 6 . Women pregnant currently breastfeed . 7 . Myopathy grade &gt; 2 8 . Known positive status human immunodeficiency virus ( HIV ) . 9 . Active hepatitis B C virus ( HBV HCV ) infection 10 . Diagnosis another invasive malignancy 11 . Any acute active infection . 12 . Known hypersensitivity study drug formulation component ( e.g. , Cremophor® ) . 13 . Treatment investigational product 30 day inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Aplidin</keyword>
	<keyword>Plitidepsin</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Pharma Mar</keyword>
</DOC>